image
Sangamo Therapeutics, Inc. SGMO
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 0.7069
7.68 %
$ 147 M
Market Cap
-1.44
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SGMO stock under the worst case scenario is HIDDEN Compared to the current market price of 0.707 USD, Sangamo Therapeutics, Inc. is HIDDEN

SGMO Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SGMO stock under the base case scenario is HIDDEN Compared to the current market price of 0.707 USD, Sangamo Therapeutics, Inc. is HIDDEN

SGMO Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SGMO stock under the best case scenario is HIDDEN Compared to the current market price of 0.707 USD, Sangamo Therapeutics, Inc. is HIDDEN

SGMO Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart SGMO

image
1M -23%
6M -32%
1Y 38%
3Y -565%
5Y -1053%
All
$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.515 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
57.8 M REVENUE
-67.20%
Growth Rates
1Year -67.20%
3Years -19.48%
5Years -10.81%
7Years 6.76%
10Years 2.34%
-104 M OPERATING INCOME
62.06%
Growth Rates
1Year 62.06%
3Years 17.23%
5Years 0.23%
7Years -9.14%
10Years -14.53%
-97.9 M NET INCOME
62.01%
Growth Rates
1Year 62.01%
3Years 18.10%
5Years -0.52%
7Years -8.72%
10Years -14.00%
-67.1 M OPERATING CASH FLOW
70.14%
Growth Rates
1Year 70.14%
3Years 33.97%
5Years 14.20%
7Years -32.06%
10Years -28.03%
37.5 M INVESTING CASH FLOW
-75.56%
Growth Rates
1Year -75.56%
3Years -46.73%
5Years 21.31%
7Years 13.75%
10Years 9.02%
28.4 M FINANCING CASH FLOW
94.52%
Growth Rates
1Year 94.52%
3Years -4.77%
5Years -27.54%
7Years -16.16%
10Years -12.02%
7.55 M REVENUE
-84.72%
Growth Rates
1Year -67.20%
3Years -19.48%
5Years -10.81%
7Years 6.76%
10Years 2.34%
-26 M OPERATING INCOME
-244.47%
Growth Rates
1Year 62.06%
3Years 17.23%
5Years 0.23%
7Years -9.14%
10Years -14.53%
-23.4 M NET INCOME
-219.23%
Growth Rates
1Year 62.01%
3Years 18.10%
5Years -0.52%
7Years -8.72%
10Years -14.00%
-3.35 M OPERATING CASH FLOW
-28.50%
Growth Rates
1Year 70.14%
3Years 33.97%
5Years 14.20%
7Years -32.06%
10Years -28.03%
1.32 M INVESTING CASH FLOW
468.24%
Growth Rates
1Year -75.56%
3Years -46.73%
5Years 21.31%
7Years 13.75%
10Years 9.02%
6.99 M FINANCING CASH FLOW
3543.84%
Growth Rates
1Year 94.52%
3Years -4.77%
5Years -27.54%
7Years -16.16%
10Years -12.02%
Balance Sheet Sangamo Therapeutics, Inc.
image
Current Assets 51.7 M
Cash & Short-Term Investments 41.9 M
Receivables 526 K
Other Current Assets 9.25 M
Non-Current Assets 49.9 M
Long-Term Investments 0
PP&E 34.8 M
Other Non-Current Assets 15.2 M
41.24 %9.10 %34.20 %14.94 %Total Assets$101.6m
Current Liabilities 45.8 M
Accounts Payable 15.5 M
Short-Term Debt 4.31 M
Other Current Liabilities 26 M
Non-Current Liabilities 33.1 M
Long-Term Debt 26.3 M
Other Non-Current Liabilities 6.81 M
19.63 %5.47 %32.98 %33.29 %8.63 %Total Liabilities$78.9m
EFFICIENCY
Earnings Waterfall Sangamo Therapeutics, Inc.
image
Revenue 57.8 M
Cost Of Revenue 0
Gross Profit 57.8 M
Operating Expenses 162 M
Operating Income -104 M
Other Expenses -6.03 M
Net Income -97.9 M
60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)58m058m(162m)(104m)6m(98m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
Averages
1Year 100.00%
3Years 54.47%
5Years 40.41%
7Years 17.65%
10Years -26.44%
-179.88% OPERATING MARGIN
-179.88%
Averages
1Year -179.88%
3Years -172.07%
5Years -158.29%
7Years -140.78%
10Years -163.23%
-169.45% NET MARGIN
-169.45%
Averages
1Year -169.45%
3Years -162.84%
5Years -150.41%
7Years -129.57%
10Years -152.87%
-430.13% ROE
-430.13%
Averages
1Year -430.13%
3Years -268.79%
5Years -175.65%
7Years -130.63%
10Years -101.72%
-96.37% ROA
-96.37%
Averages
1Year -96.37%
3Years -95.50%
5Years -64.82%
7Years -49.65%
10Years -43.07%
-172.58% ROIC
-172.58%
Averages
1Year -172.58%
3Years -145.62%
5Years -96.77%
7Years -73.62%
10Years -60.90%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sangamo Therapeutics, Inc.
image
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -97.9 M
Depreciation & Amortization 9.36 M
Capital Expenditures -267 K
Stock-Based Compensation 12.4 M
Change in Working Capital 4.51 M
Others 8.11 M
Free Cash Flow -67.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sangamo Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for SGMO of $5.67 , with forecasts ranging from a low of $2 to a high of $19 .
SGMO Lowest Price Target Wall Street Target
2 USD 182.93%
SGMO Average Price Target Wall Street Target
5.67 USD 701.62%
SGMO Highest Price Target Wall Street Target
19 USD 2587.79%
Price
Max Price Target
Min Price Target
Average Price Target
2020181816161414121210108866442200May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership Sangamo Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025. seekingalpha.com - 2 weeks ago
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM. businesswire.com - 2 weeks ago
Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Luis Santos - H.C. Wainwright Maury Raycroft - Jefferies Nicole Germino - Truist Gena Wang - Barclays Operator Good afternoon, and welcome to the Sangamo Therapeutics Fourth Quarter and Full Year 2024 Teleconference Call. seekingalpha.com - 1 month ago
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.34 per share a year ago. zacks.com - 1 month ago
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 EARNINGS CALL AND PARTICIPATION IN UPCOMING INVESTOR CONFERENCE. businesswire.com - 1 month ago
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY SHOWING SUSTAINED BENEFIT, IMPROVEMENTS IN KIDNEY FUNCTION AND FAVORABLE SAFETY PROFILE. businesswire.com - 2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ:SGMO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 months ago
8. Profile Summary

Sangamo Therapeutics, Inc. SGMO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 147 M
Dividend Yield 0.00%
Description Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Contact 501 Canal Blvd, Brisbane California, CALIFORNIA, 94005 https://www.sangamo.com
IPO Date April 6, 2000
Employees 183
Officers Ms. Prathyusha Duraibabu CPA, M.B.A. Senior Vice President, Chief Financial Officer & Principal Accounting Officer Mr. Gregory Davis Ph.D. Head of Research & Technology Ms. Louise Wilkie Head of Corporate Communications & Investor Relations Mr. Phillip Ramsey Head of Technical Operations Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. Chief Executive Officer, President & Director Ms. Stephanie J. Seiler CLP Vice President and Head of Business Development & Alliance Management Mr. David Ojala Scientist II - Discovery & Translational Research Dr. Nathalie Dubois-Stringfellow Ph.D. Senior Vice President & Chief Development Officer Mr. Scott B. Willoughby Senior Vice President, General Counsel & Corporate Secretary